HIV-associated lipodystrophy is a
syndrome that occurs in individuals with HIV who are being treated with
antiretroviral medications (typically protease inhibitors)
- This treatment results in
lipohypertrophy and lipoatrophy in various locations.
- Lipohypertrophy is characterized by the
presence of a hypertrophied dorsocervical fat pad, circumferential
expansion of the neck, breast enlargement, and abdominal visceral fat
accumulation.
- Lipoatrophy is exemplified by peripheral
fat wasting with loss of subcutaneous tissue in the face, arms, legs,
and buttocks.
- In addition, this syndrome is associated
with hyperlipidemia, insulin resistance, hyperinsulinemia, and
hyperglycemia.
|
